Research By Markets adds Market Research Report - Latest Report on Diabetic Neuropathy – Pipeline Review, H1 2020
For detailed information: https://www.researchbymarkets.com/report/diabetic-neuropathy-pipeline-review-h1-2020-605499.html
Diabetic Neuropathy – Pipeline Review, H1 2020
Diabetic Neuropathy – Pipeline Review, H1 2020, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.
“Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.”
Diabetic Neuropathy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 12, 8, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Achelios Therapeutics Inc
Applied Therapeutics Inc
Arena Pharmaceuticals Inc
Bristol-Myers Squibb Co
Commence Bio Inc
CSPC Pharmaceutical Group Ltd
Exodos Life Sciences Limited Partnership
GNT Pharma Co Ltd
Immune Pharmaceuticals Inc
Ion Channel Pharmacology LLC
Jiangsu Aosaikang Pharmaceutical Co Ltd
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Reata Pharmaceuticals Inc
Seneca Biopharma Inc
Sichuan Haisco Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
WEX Pharmaceuticals Inc
YD Life Science Co
Zhejiang Pharmaceutical Co Ltd
For queries regarding this report: https://www.researchbymarkets.com/sample-request/605499